Repligen Corp - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Repligen Corp Company

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Repligen Corp Info



Ticker SymbolRGEN

Company nameRepligen Corp

IPO dateApr 29, 1986

CEOMr. Olivier Loeillot

Number of employees1778

Security typeOrdinary Share

Fiscal year-endApr 29

AddressBuilding 1, Suite 100

CityWALTHAM

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02453

Phone17814499560

Websitehttps://www.repligen.com/

Ticker SymbolRGEN

IPO dateApr 29, 1986

CEOMr. Olivier Loeillot

Company Executives of Repligen Corp



Name

Name/Position

Position

Shareholding

Change

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

13.06K

-8.72%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

Dr. Konstantin Konstantinov, Ph.D.

Independent Director

--

Mr. Jason K. Garland

Chief Financial Officer

--

Mr. Tony John Hunt

Executive Chairman of the Board

--

Dr. Martin D. Madaus, Ph.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

13.06K

-8.72%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

No Data

By RegionUSD

Name

Revenue

Proportion

North America

89.36M

49.00%

Europe

69.30M

38.00%

APAC/Other

23.71M

13.00%

By Business

By Region

No Data

Shareholding Stats

Updated: Sat, Aug 16

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

8.37%

T. Rowe Price Associates, Inc.

6.10%

Roy T. Eddleman UEO

5.89%

Point72 Asset Management, L.P.

3.40%

Other

67.25%

Shareholders

Proportion

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

8.37%

T. Rowe Price Associates, Inc.

6.10%

Roy T. Eddleman UEO

5.89%

Point72 Asset Management, L.P.

3.40%

Other

67.25%

Shareholder Types

Shareholders

Proportion

Investment Advisor

54.39%

Investment Advisor/Hedge Fund

25.75%

Hedge Fund

12.98%

Individual Investor

6.38%

Research Firm

2.41%

Pension Fund

2.37%

Bank and Trust

0.68%

Sovereign Wealth Fund

0.60%

Family Office

0.50%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

1008

55.75M

99.10%

-5.55M

2025Q2

1028

61.98M

110.32%

-3.21M

2025Q1

1054

62.91M

111.98%

-2.72M

2024Q4

1054

61.13M

109.11%

-3.76M

2024Q3

1046

60.75M

108.48%

-6.10M

2024Q2

1039

61.28M

109.67%

-2.73M

2024Q1

1036

60.56M

108.45%

-5.41M

2023Q4

1062

62.13M

111.29%

-2.30M

2023Q3

1063

61.47M

110.27%

+2.91M

2023Q2

1050

59.01M

105.99%

+1.34M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

5.07M

9%

-2.87K

-0.06%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.71M

8.37%

-180.36K

-3.69%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.43M

6.1%

-3.13M

-47.69%

Aug 31, 2025

Roy T. Eddleman UEO

3.31M

5.89%

-67.50K

-2.00%

Dec 31, 2024

Point72 Asset Management, L.P.

1.91M

3.4%

+796.75K

+71.36%

Jun 30, 2025

State Street Investment Management (US)

1.62M

2.88%

-66.31K

-3.93%

Jun 30, 2025

Champlain Investment Partners, LLC

1.40M

2.49%

-62.91K

-4.30%

Jun 30, 2025

Fidelity Management & Research Company LLC

1.36M

2.43%

+842.96K

+161.67%

Jun 30, 2025

Sands Capital Management, LLC

1.25M

2.22%

-43.11K

-3.33%

Jun 30, 2025

Invesco Advisers, Inc.

1.25M

2.22%

-348.59K

-21.85%

Jun 30, 2025

Related ETFs



Updated: Mon, Oct 6

Name

Proportion

First Trust NYSE Arca Biotechnology Index Fund

3.05%

Invesco Biotechnology & Genome ETF

2.57%

Congress SMid Growth ETF

1.97%

iShares Health Innovation Active ETF

1.52%

VanEck Biotech ETF

1.27%

Franklin Genomic Advancements ETF

0.98%

WisdomTree BioRevolution Fund

0.98%

Pacer US Export Leaders ETF

0.87%

iShares Biotechnology ETF

0.63%

First Trust Multi-Manager Small Cap Opportunities ETF

0.5%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.05%

Invesco Biotechnology & Genome ETF

Proportion2.57%

Congress SMid Growth ETF

Proportion1.97%

iShares Health Innovation Active ETF

Proportion1.52%

VanEck Biotech ETF

Proportion1.27%

Franklin Genomic Advancements ETF

Proportion0.98%

WisdomTree BioRevolution Fund

Proportion0.98%

Pacer US Export Leaders ETF

Proportion0.87%

iShares Biotechnology ETF

Proportion0.63%

First Trust Multi-Manager Small Cap Opportunities ETF

Proportion0.5%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data